Home › Companies › PLIANT THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2025: 6 items on PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025: 3 approved · 3 passed (calculated).
Significant dissent: 2 directors (33.1%, 20.9% against).
Notable dissent: 1 director (13.4% against); 1 say-on-pay vote (77.1% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Tang Capital (13D, 9.6%, as of March 10, 2025) · BML Capital (13F, 2.5%, as of September 30, 2026)
Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John Curnutte, M.D., Ph.D. | 34,534,316 | -- | -- | 5,351,841 | -- | 87% | Passed (calculated) | — |
| Elect Director: Katharine Knobil, M.D. | 26,681,127 | -- | -- | 13,205,030 | -- | 67% | Passed (calculated) | — |
| Elect Director: Thomas McCourt | 31,557,399 | -- | -- | 8,328,758 | -- | 79% | Passed (calculated) | — |
| 2. On a non-binding advisory basis, the compensation of the Company's named executive officers | 30,037,373 | 8,937,835 | 910,949 | -- | -- | 77% | Approved | — |
| As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law. The voting | 35,232,687 | 3,771,806 | 881,664 | -- | -- | 90% | Approved | — |
| 4. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 50,796,112 | 506,011 | 931,004 | -- | -- | 99.0% | Approved | — |
Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
147 asset managers disclosed a vote on at least one PLIANT THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: John Curnutte, M.D., Ph.D.
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: John Curnutte, M.D., Ph.D.”): 34,534,316 for, 5,351,841 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 8,390,606 for, 539,836 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 2,854,683 | 0 | 0 | 0 | For |
| Fidelity | 1,210,262 | 0 | 0 | 12,081 | For |
| Charles Schwab | 390,723 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 207,392 | Withhold |
| TIAA | 0 | 0 | 0 | 154,332 | Withhold |
| Equitable | 92,481 | 0 | 0 | 58,180 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,130 | 0 | 0 | 0 | For |
| Lincoln Financial | 34,937 | 0 | 0 | 44,809 | Mixed |
| Invesco | 36,203 | 0 | 0 | 0 | For |
| Northern Trust | 35,294 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,988 | 0 | 0 | 0 | For |
| Global X | 33,545 | 0 | 0 | 0 | For |
| Pacific Life | 29,030 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 27,338 | Withhold |
| Bridge Builder Trust | 25,462 | 0 | 0 | 0 | For |
| John Hancock | 21,653 | 0 | 0 | 1,976 | Mixed |
| CLEARWATER INVESTMENT TRUST | 19,488 | 0 | 0 | 0 | For |
| Goldman Sachs | 18,363 | 0 | 0 | 0 | For |
| Voya | 16,319 | 0 | 0 | 0 | For |
| JPMorgan | 15,922 | 0 | 0 | 0 | For |
| ProShares | 14,009 | 0 | 0 | 0 | For |
| SEI | 11,200 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| DWS | 8,498 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
67% Majority: yes · of votes cast
Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: Katharine Knobil, M.D.
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Katharine Knobil, M.D.”): 26,681,127 for, 13,205,030 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 5,080,801 for, 3,849,641 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 2,854,683 | Withhold |
| Fidelity | 1,188,301 | 0 | 0 | 34,042 | For |
| Charles Schwab | 390,723 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 207,392 | Withhold |
| TIAA | 0 | 0 | 0 | 154,332 | Withhold |
| Equitable | 0 | 0 | 0 | 150,661 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 94,130 | Withhold |
| Lincoln Financial | 42,300 | 0 | 0 | 37,446 | Mixed |
| Invesco | 0 | 0 | 0 | 36,203 | Withhold |
| Northern Trust | 0 | 0 | 0 | 35,294 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 33,988 | Withhold |
| Global X | 33,545 | 0 | 0 | 0 | For |
| Pacific Life | 0 | 0 | 0 | 29,030 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 27,338 | Withhold |
| Bridge Builder Trust | 0 | 0 | 0 | 25,462 | Withhold |
| John Hancock | 0 | 0 | 0 | 23,629 | Withhold |
| CLEARWATER INVESTMENT TRUST | 19,488 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 18,363 | Withhold |
| Voya | 0 | 0 | 0 | 16,319 | Withhold |
| JPMorgan | 15,922 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 14,009 | Withhold |
| SEI | 11,200 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| DWS | 0 | 0 | 0 | 8,498 | Withhold |
Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect three class II directors named in the proxy statement to our Board of Directors: Thomas McCourt
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas McCourt”): 31,557,399 for, 8,328,758 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 7,895,409 for, 1,035,033 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 2,854,683 | 0 | 0 | 0 | For |
| Fidelity | 1,210,262 | 0 | 0 | 12,081 | For |
| Charles Schwab | 0 | 0 | 0 | 390,723 | Withhold |
| Dimensional | 0 | 0 | 0 | 207,392 | Withhold |
| TIAA | 0 | 0 | 0 | 154,332 | Withhold |
| Equitable | 92,481 | 0 | 0 | 58,180 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,130 | 0 | 0 | 0 | For |
| Lincoln Financial | 42,300 | 0 | 0 | 37,446 | Mixed |
| Invesco | 36,203 | 0 | 0 | 0 | For |
| Northern Trust | 35,294 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 33,988 | Withhold |
| Global X | 33,545 | 0 | 0 | 0 | For |
| Pacific Life | 29,030 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 27,338 | Withhold |
| Bridge Builder Trust | 25,462 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 23,629 | Withhold |
| CLEARWATER INVESTMENT TRUST | 19,488 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 18,363 | Withhold |
| Voya | 16,319 | 0 | 0 | 0 | For |
| JPMorgan | 15,922 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 14,009 | Withhold |
| SEI | 11,200 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 9,535 | Withhold |
| DWS | 0 | 0 | 0 | 8,498 | Withhold |
Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).
90% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF PLIANT THERAPEUTICS, INC. AS PERMITTED BY DELAWARE LAW.
PLIANT THERAPEUTICS INC.’s own tally for this item (“Proposal 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company a”): 35,232,687 for, 3,771,806 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 8,846,038 for, 84,404 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 2,854,683 | 0 | 0 | 0 | For |
| Fidelity | 1,222,343 | 0 | 0 | 0 | For |
| Charles Schwab | 390,723 | 0 | 0 | 0 | For |
| Dimensional | 207,392 | 0 | 0 | 0 | For |
| TIAA | 154,332 | 0 | 0 | 0 | For |
| Equitable | 150,661 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 94,130 | 0 | 0 | 0 | For |
| Lincoln Financial | 79,746 | 0 | 0 | 0 | For |
| Invesco | 36,203 | 0 | 0 | 0 | For |
| Northern Trust | 35,294 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,988 | 0 | 0 | 0 | For |
| Global X | 0 | 33,545 | 0 | 0 | Against |
| Pacific Life | 29,030 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,338 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 25,462 | 0 | 0 | 0 | For |
| John Hancock | 23,629 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 0 | 19,488 | 0 | 0 | Against |
| Goldman Sachs | 18,363 | 0 | 0 | 0 | For |
| Voya | 16,319 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 15,922 | 0 | 0 | Against |
| ProShares | 14,009 | 0 | 0 | 0 | For |
| SEI | 0 | 11,200 | 0 | 0 | Against |
| Jackson National | 9,535 | 0 | 0 | 0 | For |
| DWS | 8,498 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
77% Approved · of votes cast
Prior year: 45.3% for (June 13, 2024 meeting) ▲ 31.7 pts
Description as filed by funds: To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.
PLIANT THERAPEUTICS INC.’s own tally for this item (“2. On a non-binding advisory basis, the compensation of the Company's named executive officers”): 30,037,373 for, 8,937,835 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2: The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 2,854,683 | 0 | 0 | 0 | For |
| Fidelity | 1,222,343 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 390,723 | 0 | 0 | Against |
| Dimensional | 0 | 207,392 | 0 | 0 | Against |
| TIAA | 0 | 154,332 | 0 | 0 | Against |
| Equitable | 92,481 | 58,180 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,130 | 0 | 0 | 0 | For |
| Lincoln Financial | 42,300 | 37,446 | 0 | 0 | Mixed |
| Invesco | 0 | 36,203 | 0 | 0 | Against |
| Northern Trust | 35,294 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 33,988 | 0 | 0 | Against |
| Global X | 0 | 33,545 | 0 | 0 | Against |
| Pacific Life | 29,030 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 27,338 | 0 | 0 | Against |
| Bridge Builder Trust | 25,462 | 0 | 0 | 0 | For |
| John Hancock | 0 | 23,629 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 0 | 19,488 | 0 | 0 | Against |
| Goldman Sachs | 0 | 18,363 | 0 | 0 | Against |
| Voya | 0 | 16,319 | 0 | 0 | Against |
| JPMorgan | 15,922 | 0 | 0 | 0 | For |
| ProShares | 0 | 14,009 | 0 | 0 | Against |
| SEI | 0 | 11,200 | 0 | 0 | Against |
| Jackson National | 0 | 9,535 | 0 | 0 | Against |
| DWS | 0 | 8,498 | 0 | 0 | Against |
Fund voting reports, all 39 managers: 7,786,486 for, 1,143,956 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 5,399,681 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 2,964,337 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 2,367,310 | 0 | 0 | 0 | For |
| Madison Avenue Partners, LP | 0 | 2,215,765 | 0 | 0 | Against |
| TRV GP IV, LLC | 2,132,867 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,030,963 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,927,988 | 0 | 0 | 0 | For |
| BlackRock | 1,907,627 | 880 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,336,128 | 0 | 0 | 0 | For |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 0 | 1,059,466 | 0 | 0 | Against |
| State Street | 971,288 | 22,632 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 0 | 0 | 850,000 | 0 | Abstain |
| Bessemer Trust CO of Delaware, N.A. | 0 | 536,888 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 532,118 | 0 | 0 | Against |
| BESSEMER TRUST Co OF FLORIDA | 0 | 532,118 | 0 | 0 | Against |
| Bessemer Trust Co of Nevada, National Association | 0 | 532,118 | 0 | 0 | Against |
| Charles Schwab | 0 | 390,723 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 0 | 346,703 | 0 | 0 | Against |
| ArrowMark Colorado Holdings LLC | 0 | 281,189 | 0 | 0 | Against |
| Northern Trust | 253,903 | 4,991 | 0 | 0 | For |
| Graham Capital Management, L.P. | 0 | 231,343 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 208,147 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 190,094 | 0 | 0 | Against |
| Vanguard | 160,596 | 23,162 | 0 | 0 | Mixed |
| Nuveen | 0 | 156,004 | 0 | 0 | Against |
Institutional-manager reports, all 121 managers: 21,905,274 for, 8,674,353 against, 850,000 abstained, 4,500 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.0% Approved · of votes cast
Prior year: 100.0% for (June 13, 2024 meeting) ▼ 1.0 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
PLIANT THERAPEUTICS INC.’s own tally for this item (“4. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 50,796,112 for, 506,011 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 8,930,208 for, 234 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,365,967 | 0 | 0 | 0 | For |
| BlackRock | 2,854,683 | 0 | 0 | 0 | For |
| Fidelity | 1,222,343 | 0 | 0 | 0 | For |
| Charles Schwab | 390,723 | 0 | 0 | 0 | For |
| Dimensional | 207,392 | 0 | 0 | 0 | For |
| TIAA | 154,332 | 0 | 0 | 0 | For |
| Equitable | 150,661 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 94,130 | 0 | 0 | 0 | For |
| Lincoln Financial | 79,746 | 0 | 0 | 0 | For |
| Invesco | 36,203 | 0 | 0 | 0 | For |
| Northern Trust | 35,294 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,988 | 0 | 0 | 0 | For |
| Global X | 33,545 | 0 | 0 | 0 | For |
| Pacific Life | 29,030 | 0 | 0 | 0 | For |
| T. Rowe Price | 27,338 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 25,462 | 0 | 0 | 0 | For |
| John Hancock | 23,629 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 19,488 | 0 | 0 | 0 | For |
| Goldman Sachs | 18,363 | 0 | 0 | 0 | For |
| Voya | 16,319 | 0 | 0 | 0 | For |
| JPMorgan | 15,922 | 0 | 0 | 0 | For |
| ProShares | 14,009 | 0 | 0 | 0 | For |
| SEI | 11,200 | 0 | 0 | 0 | For |
| Jackson National | 9,535 | 0 | 0 | 0 | For |
| DWS | 8,498 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. All 39 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,386,278 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.48% |
| 2 | BlackRock | 4.65% |
| 3 | Fidelity | 1.99% |
| 4 | Charles Schwab | 0.64% |
| 5 | Dimensional | 0.34% |
| 6 | TIAA | 0.25% |
| 7 | Equitable | 0.25% |
| 8 | QUANTITATIVE MASTER SERIES LLC | 0.15% |
| 9 | Lincoln Financial | 0.13% |
| 10 | Invesco | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 8.80% |
| 2 | Blue Owl Capital Holdings LP | 4.83% |
| 3 | Cormorant Asset Management, LP | 3.86% |
| 4 | Madison Avenue Partners, LP | 3.61% |
| 5 | TRV GP IV, LLC | 3.47% |
| 6 | Woodline Partners LP | 3.31% |
| 7 | Redmile Group, LLC | 3.14% |
| 8 | BlackRock | 3.11% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.18% |
| 10 | BESSEMER TRUST Co NATIONAL ASSOCIATION | 1.73% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Tang Capital Management LLC | 5,859,044 | 9.54% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Deep Track Capital, LP | 5,750,000 | 9.37% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| BlackRock | 5,241,759 | 8.54% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 3,334,575 | 5.43% | Form 13F, quarter ended March 31, 2025 |
| Paradigm Biocapital Advisors LP | 3,059,411 | 4.98% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Morgan Stanley | 3,051,514 | 4.97% | Form 13F, quarter ended March 31, 2025 |
| Kenneth Griffin | 3,042,133 | 4.96% | Schedule 13G, filed February 9, 2026 |
| Redmile Group, LLC | 2,895,478 | 4.72% | Schedule 13G, filed February 14, 2025 |
| Bernard Coulie, M.D., Ph.D., M.B.A. | 2,029,261 | 3.31% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Woodline Partners LP | 2,026,191 | 3.30% | Schedule 13G, filed February 17, 2026 |
Percentages above are of 61,386,278 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated May 1, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At PLIANT THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 147 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 851 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the resolution approving Named Executive Officers… — PLIANT THERAPEUTICS INC.'s filing reports the proposal as approved, with 77% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated May 1, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “PLIANT THERAPEUTICS (PLRX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pliant-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.